<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>LiquidMammo™ | Breast cancer screening, reimagined</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="description" content="LiquidMammo is a microRNA-based liquid biopsy for early breast cancer detection—non-invasive and designed to complement imaging, especially where mammography has limitations." />
  <link rel="stylesheet" href="assets/css/styles.css" />
  <link rel="icon" href="/favicon.png" type="image/png" />
</head>
<body>
<header class="container">
  <nav>
    <div class="brand">
      <img src="assets/logos/liquidmammo-logo.png" alt="LiquidMammo logo" />
      <strong>LiquidMammo™</strong>
    </div>
    <div style="display:flex;gap:14px;flex-wrap:wrap">
      <a href="how-it-works.html">How It Works</a>
      <a href="science.html">Science</a>
      <a href="patients.html">Patients</a>
      <a href="clinicians.html">Clinicians</a>
      <a href="evidence.html">Evidence</a>
      <a href="biobank.html">Biobank</a>
      <a href="pricing.html">Pricing</a>
      <a href="contact.html">Contact</a>
      <a href="privacy.html">Privacy</a>
    </div>
  </nav>
</header>

<main>
  <section class="hero">
    <div class="container grid grid-2">
      <div>
        <h1>Breast cancer screening, reimagined.</h1>
        <p class="kicker">A microRNA blood test designed to complement imaging—non‑invasive and clinician‑ordered.</p>
        <p class="small">
          Screening mammography is valuable but not perfect; false‑negatives occur and are more likely in dense breasts.
          Many screening programs also experience frequent false‑positives.
        </p>
        <div style="margin-top:10px">
          <a class="btn" href="patients.html#join">Join Early Access</a>
          <a class="btn secondary" href="clinicians.html#enroll">Clinician Enrollment</a>
        </div>
        <p class="notice" style="margin-top:14px">
          Regulatory: LiquidMammo is being developed as a <strong>CLIA Laboratory Developed Test (LDT)</strong>; it is not yet FDA‑cleared/approved. Use is at the ordering clinician’s discretion within applicable regulations.
        </p>
      </div>
      <div aria-hidden="true">
        <div class="card">
          <h3>Why a blood‑based screen matters</h3>
          <ul class="list-tight">
            <li>False‑negative mammograms occur (≈1 in 8 overall).</li>
            <li>False‑positives are common over a decade of screening.</li>
            <li>Missed cancers (interval cancers) are more common in dense breasts.</li>
          </ul>
        </div>
      </div>
    </div>
  </section>

  <section class="container section grid grid-2">
    <div class="card">
      <h2>What LiquidMammo does</h2>
      <p><span class="badge">Screening support</span> A blood test that raises or lowers concern so clinicians can fast‑track imaging when warranted.</p>
      <p><span class="badge">Actionable biology</span> If elevated, the report maps results to the three clinical groups—HR+/HER2‑, HER2+, and triple‑negative—to guide the next test. (Imaging/biopsy confirm.)</p>
    </div>
    <div class="card">
      <h2>Clinically motivated</h2>
      <p>Evidence shows mammography can miss cancers—particularly in dense tissue—and false‑negative rates have risen in large U.S. datasets.</p>
      <p class="small">A non‑invasive test may improve participation and complement imaging pathways.</p>
    </div>
  </section>

  <section class="container section">
    <h2>Built for clinical workflows</h2>
    <div class="grid grid-2">
      <div class="card">
        <h3>Designed for density limitations</h3>
        <p>Dense breast tissue can obscure cancers on mammograms and is associated with higher interval cancer rates; adjunct methods can help address this gap.</p>
        <p class="small">50–74% of women in their 40s have dense breasts, and mammography sensitivity drops to ≈61% in extremely dense tissue (BCSC data). <a href="evidence.html">See the data →</a></p>
      </div>
      <div class="card">
        <h3>Grounded in published evidence</h3>
        <p>We reference and align with publicly available data on screening performance (false‑negatives, false‑positives, detection rates per 1,000).</p>
      </div>
    </div>
  </section>
</main>

<footer>
  <div class="container footer-grid">
    <div>
      <strong>LiquidMammo™</strong><br/>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC, and operates out of LabCentral, Cambridge, MA (MIT innovation ecosystem).
      </p>
    </div>
    <div class="footer-logo" style="justify-content:flex-end;text-align:right">
      <img src="assets/logos/multiomics-logo.png" alt="MultiOmics Inc. logo (subtle)" />
      <div class="footer-note" style="line-height:1.2">Developed by<br/>MultiOmics Inc.</div>
    </div>
  </div>
  <div class="container footer-note">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. • <a href="privacy.html">Privacy & Compliance</a> • <a href="contact.html">Order / Kits</a>
  </div>
</footer>
</body>

</html>
